S&P 500   3,367.31 (+0.20%)
DOW   27,993.13 (+0.73%)
QQQ   268.39 (-0.71%)
AAPL   443.42 (-1.66%)
MSFT   206.16 (-1.00%)
FB   260.38 (-1.00%)
GOOGL   1,498.00 (+0.08%)
AMZN   3,121.05 (-0.86%)
NVDA   438.62 (-1.79%)
CGC   17.44 (-2.73%)
BABA   249.78 (+0.66%)
TSLA   1,392.00 (-1.87%)
GE   6.80 (+1.95%)
MU   48.65 (-1.02%)
AMD   78.80 (-4.18%)
T   30.45 (+0.83%)
F   7.32 (+3.24%)
ACB   10.12 (-0.98%)
GILD   68.06 (-0.66%)
NFLX   471.24 (-2.51%)
DIS   131.82 (+2.35%)
BAC   27.25 (+2.60%)
BA   186.10 (+3.73%)
S&P 500   3,367.31 (+0.20%)
DOW   27,993.13 (+0.73%)
QQQ   268.39 (-0.71%)
AAPL   443.42 (-1.66%)
MSFT   206.16 (-1.00%)
FB   260.38 (-1.00%)
GOOGL   1,498.00 (+0.08%)
AMZN   3,121.05 (-0.86%)
NVDA   438.62 (-1.79%)
CGC   17.44 (-2.73%)
BABA   249.78 (+0.66%)
TSLA   1,392.00 (-1.87%)
GE   6.80 (+1.95%)
MU   48.65 (-1.02%)
AMD   78.80 (-4.18%)
T   30.45 (+0.83%)
F   7.32 (+3.24%)
ACB   10.12 (-0.98%)
GILD   68.06 (-0.66%)
NFLX   471.24 (-2.51%)
DIS   131.82 (+2.35%)
BAC   27.25 (+2.60%)
BA   186.10 (+3.73%)
S&P 500   3,367.31 (+0.20%)
DOW   27,993.13 (+0.73%)
QQQ   268.39 (-0.71%)
AAPL   443.42 (-1.66%)
MSFT   206.16 (-1.00%)
FB   260.38 (-1.00%)
GOOGL   1,498.00 (+0.08%)
AMZN   3,121.05 (-0.86%)
NVDA   438.62 (-1.79%)
CGC   17.44 (-2.73%)
BABA   249.78 (+0.66%)
TSLA   1,392.00 (-1.87%)
GE   6.80 (+1.95%)
MU   48.65 (-1.02%)
AMD   78.80 (-4.18%)
T   30.45 (+0.83%)
F   7.32 (+3.24%)
ACB   10.12 (-0.98%)
GILD   68.06 (-0.66%)
NFLX   471.24 (-2.51%)
DIS   131.82 (+2.35%)
BAC   27.25 (+2.60%)
BA   186.10 (+3.73%)
S&P 500   3,367.31 (+0.20%)
DOW   27,993.13 (+0.73%)
QQQ   268.39 (-0.71%)
AAPL   443.42 (-1.66%)
MSFT   206.16 (-1.00%)
FB   260.38 (-1.00%)
GOOGL   1,498.00 (+0.08%)
AMZN   3,121.05 (-0.86%)
NVDA   438.62 (-1.79%)
CGC   17.44 (-2.73%)
BABA   249.78 (+0.66%)
TSLA   1,392.00 (-1.87%)
GE   6.80 (+1.95%)
MU   48.65 (-1.02%)
AMD   78.80 (-4.18%)
T   30.45 (+0.83%)
F   7.32 (+3.24%)
ACB   10.12 (-0.98%)
GILD   68.06 (-0.66%)
NFLX   471.24 (-2.51%)
DIS   131.82 (+2.35%)
BAC   27.25 (+2.60%)
BA   186.10 (+3.73%)
Log in

NYSE:ZYMEZymeworks Stock Price, Forecast & News

$30.77
-0.09 (-0.29 %)
(As of 08/11/2020 02:48 PM ET)
Add
Compare
Today's Range
$30.04
Now: $30.77
$31.21
50-Day Range
$29.21
MA: $33.29
$40.00
52-Week Range
$20.33
Now: $30.77
$52.75
Volume113,187 shs
Average Volume379,119 shs
Market Capitalization$1.40 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.02
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer; ZW49, a bispecific antibody-drug conjugate that is in preclinical stage for treating breast and gastric cancers, and solid tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Read More
Zymeworks logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.66 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Previous SymbolNASDAQ:ZYME
CUSIPN/A
Phone604-678-1388

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$29.54 million
Book Value$6.21 per share

Profitability

Net Income$-145,440,000.00
Net Margins-569.13%

Miscellaneous

Employees180
Market Cap$1.40 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$30.77
-0.09 (-0.29 %)
(As of 08/11/2020 02:48 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZYME News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zymeworks (NYSE:ZYME) Frequently Asked Questions

How has Zymeworks' stock price been impacted by Coronavirus?

Zymeworks' stock was trading at $32.26 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ZYME shares have decreased by 4.7% and is now trading at $30.7450.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Zymeworks?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last year. There are currently 1 hold rating, 10 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Zymeworks
.

When is Zymeworks' next earnings date?

Zymeworks is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Zymeworks
.

How were Zymeworks' earnings last quarter?

Zymeworks Inc (NYSE:ZYME) announced its quarterly earnings data on Wednesday, August, 5th. The company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.09. Zymeworks had a negative return on equity of 44.06% and a negative net margin of 569.13%.
View Zymeworks' earnings history
.

What price target have analysts set for ZYME?

12 Wall Street analysts have issued twelve-month target prices for Zymeworks' stock. Their forecasts range from $42.00 to $70.00. On average, they expect Zymeworks' share price to reach $52.91 in the next year. This suggests a possible upside of 72.1% from the stock's current price.
View analysts' price targets for Zymeworks
.

Has Zymeworks been receiving favorable news coverage?

News stories about ZYME stock have been trending neutral on Tuesday, according to InfoTrie. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zymeworks earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days.
View the latest news about Zymeworks
.

Are investors shorting Zymeworks?

Zymeworks saw a decline in short interest during the month of February. As of February 15th, there was short interest totaling 440,700 shares, a decline of 17.2% from the January 31st total of 532,000 shares. Based on an average trading volume of 423,900 shares, the days-to-cover ratio is currently 1.0 days. Approximately 1.4% of the shares of the company are short sold.
View Zymeworks' Short Interest
.

Who are some of Zymeworks' key competitors?

What other stocks do shareholders of Zymeworks own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Just Energy Group (JE), Advanced Micro Devices (AMD), Just Energy Group (JE), NVIDIA (NVDA), Cronos Group (CRON), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Alibaba Group (BABA), Paypal (PYPL) and Aurora Cannabis (ACB).

Who are Zymeworks' key executives?

Zymeworks' management team includes the following people:
  • Dr. Ali Tehrani, Co-Founder, Pres, CEO & Director (Age 47)
  • Mr. Neil A. Klompas C.A., CPA, CPA, CA, Chief Financial Officer (Age 47)
  • Dr. Anthony J. Polverino, Chief Scientific Officer & Exec. VP of Early Devel. (Age 56)
  • Dr. Diana F. Hausman, Chief Medical Officer (Age 56)
  • Dr. Surjit Dixit, VP of Technology (Age 46)

When did Zymeworks IPO?

(ZYME) raised $65 million in an initial public offering on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity served as the underwriters for the IPO and Cormark Securities was co-manager.

What is Zymeworks' stock symbol?

Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."

Who are Zymeworks' major shareholders?

Zymeworks' stock is owned by a variety of retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (0.76%), Peregrine Capital Management LLC (0.44%), Raymond James & Associates (0.29%), Picton Mahoney Asset Management (0.26%), Swiss National Bank (0.17%) and Taylor Wealth Management Partners (0.15%). Company insiders that own Zymeworks stock include Ali Tehrani, David Kai Yuen Poon, Eli & Co Lilly, Neil A Klompas and Troy Cox.
View institutional ownership trends for Zymeworks
.

Which institutional investors are selling Zymeworks stock?

ZYME stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc., Picton Mahoney Asset Management, Taylor Wealth Management Partners, UBS Group AG, Chartwell Investment Partners LLC, and Cornerstone Investment Partners LLC.
View insider buying and selling activity for Zymeworks
.

Which institutional investors are buying Zymeworks stock?

ZYME stock was acquired by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Swiss National Bank, Moody Aldrich Partners LLC, Evoke Wealth LLC, Peregrine Capital Management LLC, Trexquant Investment LP, Virtu Financial LLC, and SG Americas Securities LLC. Company insiders that have bought Zymeworks stock in the last two years include Ali Tehrani, and Troy Cox.
View insider buying and selling activity for Zymeworks
.

How do I buy shares of Zymeworks?

Shares of ZYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zymeworks' stock price today?

One share of ZYME stock can currently be purchased for approximately $30.75.

How big of a company is Zymeworks?

Zymeworks has a market capitalization of $1.40 billion and generates $29.54 million in revenue each year. The company earns $-145,440,000.00 in net income (profit) each year or ($3.83) on an earnings per share basis. Zymeworks employs 180 workers across the globe.

What is Zymeworks' official website?

The official website for Zymeworks is www.zymeworks.com.

How can I contact Zymeworks?

Zymeworks' mailing address is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. The company can be reached via phone at 604-678-1388 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.